A Phase 3 interventional study of Sitagliptin and Placebo to sitagliptin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 13th largest by enrollment of the 197 interventional ones that give a count, is one of 11 that started in 2016, is one of 74 in phase 3, and was the 169th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 11 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 746 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 19th largest by enrollment of the 170 interventional ones that give a count, is one of 3 that started in 2016, is one of 86 in phase 3, and was the 174th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and titrate insulin glargine (LANTUS®) based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L). A primary hypothesis of this trial is that after 30 weeks, continuing sitagliptin results in a greater reduction of hemoglobin A1C (A1C) relative to withdrawing sitagliptin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Be on one of the following treatment regimens:
Stable dose of sitagliptin (100 mg/day) and metformin IR or XR (metformin) (≥1500 mg/day) either co-administered or as a fixed dose combination (FDC) for ≥12 weeks with between 7.5% and 11.0%, inclusive.
OR
Stable dose of metformin (≥1500 mg/day) and another dipeptidyl peptidase-4 (DPP-4) inhibitor (at maximum labeled dose, other than sitagliptin, either co-administered or as a FDC, for ≥12 weeks with A1C between 7.5% and 11.0%, inclusive.
OR
Stable dose of sitagliptin (100 mg/day) and metformin (≥1500 mg/day) either co administered or as a FDC, and a sulfonylurea for ≥12 weeks OR stable dose of metformin (≥1500 mg/day) and a sulfonylurea administered as a FDC and sitagliptin (100 mg/day) with A1C between 7.0% and 10.0%, inclusive.
OR
Meet one of the following categories:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sitagliptin 100 mg, oral, once daily for 30 weeks
Drug: Sitagliptin · Drug: Metformin · Drug: Metformin XR · Drug: Insulin glargine
Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
Drug: Placebo to sitagliptin · Drug: Metformin · Drug: Metformin XR · Drug: Insulin glargine
Sitagliptin 100 mg, oral, once daily for 30 weeks
Also known as: Januvia®
Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).
At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.
Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.
Also known as: LANTUS®)
Change From Baseline in A1C at Week 30
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 30 A1C minus the Week 0 A1C.
Time frame: Baseline and Week 30
Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)
Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.
Time frame: Up to 30 weeks
Percentage of Participants Who Discontinued Study Drug Due to an AE
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 30 weeks
Percentage of Participants Who Experienced One or More Adverse Events (AEs)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 32 weeks
Percentage of Participants With Events of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)
Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The incidence (number of participants with ≥1 event divided by number of participants) of documented symptomatic hypoglycemia was determined.
Time frame: Up to 30 weeks
Change From Baseline in Total Daily Insulin Dose (Units) at Week 30
Change from baseline reflects the Week 30 total daily insulin dose minus the Week 0 total daily insulin dose. The Week 0 total daily insulin dose was 0, by definition, because insulin was not administered at baseline.
Time frame: Baseline and Week 30
Event Rate of Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)
Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.
Time frame: Up to 30 weeks
Event Rate of Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)
Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.
Time frame: Up to 30 weeks
Percentage of Participants With Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)
Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L).
Time frame: Up to 30 weeks
Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol) at Week 30
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.
Time frame: Week 30
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at Week 0).
Time frame: Baseline and Week 30
Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)
Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.
Time frame: Up to 30 weeks
Percentage of Participants With Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)
Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L).
Time frame: Up to 30 weeks
Percentage of Participants With Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)
Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L).
Time frame: Up to 30 weeks
Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) up to Week 30
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.
Time frame: Week 30
A total of 746 participants were randomized across 149 study sites in 22 countries.
| Milestone | Sitagliptin | Placebo |
|---|---|---|
| Started | 374 | 372 |
| Treated | 373 | 370 |
| Completed | 361 | 347 |
| Not completed | 13 | 25 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 5 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Physician decision | 3 | 4 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Screen failure | 1 | 2 |
| Withdrew: Site discontinued study participation | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 7 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 30 A1C minus the Week 0 A1C.
| Percent A1C | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in A1C at Week 30 | -1.88 ± -1.98 | -1.42 ± -1.52 |
Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.
| Events/Participant-Years | Sitagliptin | Placebo |
|---|---|---|
| Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) | 1.55 ± 1.22 | 2.12 ± 1.70 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants Who Discontinued Study Drug Due to an AE | 1.3 | 1.6 |
Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The incidence (number of participants with ≥1 event divided by number of participants) of documented symptomatic hypoglycemia was determined.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants With Events of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) | 33.5 ± 28.5 | 37.7 ± 32.7 |
Change from baseline reflects the Week 30 total daily insulin dose minus the Week 0 total daily insulin dose. The Week 0 total daily insulin dose was 0, by definition, because insulin was not administered at baseline.
| Insulin Units | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in Total Daily Insulin Dose (Units) at Week 30 | 53.2 ± 48.5 | 61.3 ± 56.5 |
Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.
| Events/Participant-Years | Sitagliptin | Placebo |
|---|---|---|
| Event Rate of Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) | 5.05 ± 4.34 | 6.21 ± 5.33 |
Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.
| Events/Participant-Years | Sitagliptin | Placebo |
|---|---|---|
| Event Rate of Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L) | 0.30 ± 0.20 | 0.36 ± 0.25 |
Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L).
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants With Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L) | 12.4 ± 8.9 | 13.6 ± 10.0 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol) at Week 30 | 54.2 | 35.4 |
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at Week 0).
| mg/dL | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30 | -84.8 ± -90.0 | -78.3 ± -83.5 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants Who Experienced One or More Adverse Events (AEs) | 57.9 | 60.0 |
Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.
| Events/Participant-Years | Sitagliptin | Placebo |
|---|---|---|
| Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L) | 0.17 ± 0.10 | 0.22 ± 0.14 |
Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L).
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants With Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) | 66.8 ± 61.9 | 68.0 ± 63.2 |
Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L).
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants With Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L) | 7.6 ± 4.9 | 8.3 ± 5.4 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) up to Week 30 | 15.3 | 10.0 |
Collected over Up to 32 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin | 0/373 (0%) | 14/373 (3.8%) | 79/373 (21.2%) |
| Placebo | 2/370 (0.5%) | 18/370 (4.9%) | 72/370 (19.5%) |
| Event | Sitagliptin | Placebo |
|---|---|---|
| Cerebrovascular accidentNervous system disorders | 0/373 | 2/370 |
| Ischaemic strokeNervous system disorders | 0/373 | 2/370 |
| Acute myocardial infarctionCardiac disorders | 1/373 | 1/370 |
| Coronary artery diseaseCardiac disorders | 1/373 | 1/370 |
| Myocardial infarctionCardiac disorders | 0/373 | 1/370 |
| PhimosisCongenital, familial and genetic disorders | 0/373 | 1/370 |
| ColitisGastrointestinal disorders | 0/373 | 1/370 |
| BronchitisInfections and infestations | 0/373 | 1/370 |
| PyelonephritisInfections and infestations | 0/373 | 1/370 |
| TracheitisInfections and infestations | 0/373 | 1/370 |
| Event | Sitagliptin | Placebo |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 35/373 | 24/370 |
| NasopharyngitisInfections and infestations | 24/373 | 32/370 |
| HeadacheNervous system disorders | 25/373 | 19/370 |
The overall number of baseline participants included all randomized participants.
| Age, Continuous(years) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 58.5 ± 9.5 | 58.1 ± 9.7 | 58.3 ± 9.6 |
| Age, Customized(Participants) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 275 | 272 | 547 |
| From 65-84 years | 99 | 100 | 199 |
| 85 years and over | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Female | 204 | 181 | 385 |
| Male | 170 | 191 | 361 |
| Race (NIH/OMB)(Participants) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 19 | 18 | 37 |
| Asian | 42 | 37 | 79 |
| Native Hawaiian or Other Pacific Islander | 6 | 1 | 7 |
| Black or African American | 12 | 12 | 24 |
| White | 259 | 270 | 529 |
| More than one race | 34 | 34 | 68 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Geographic Region(Participants) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Asia | 36 | 26 | 62 |
| Europe | 158 | 172 | 330 |
| Latin America | 85 | 83 | 168 |
| North America | 80 | 78 | 158 |
| Other | 15 | 13 | 28 |
| Hemoglobin A1C (A1C)(Percent A1C) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 8.8 ± 0.9 | 8.8 ± 1.0 | 8.8 ± 0.9 |
| Fasting Plasma Glucose (FPG)(mg/dL) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 199.0 ± 50.8 | 201.2 ± 51.8 | 200.1 ± 51.3 |
| Estimated Glomerular Filtration Rate(mL/min/1.73 m^2) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 103.7 ± 30.3 | 106.4 ± 28.1 | 105.1 ± 29.2 |
2 further baseline measures are reported on the registry.
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from May 2016 to primary completion in Jan 2018, 20 months.
Results were first posted in Feb 2019, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin